Last Updated: 14 Nov 2024
Executive Summary
Becton Dickinson and Company (BDX) is a leading global medical technology company with a market capitalization of $67.8 billion. The company's strong financial performance, driven by consistent revenue growth and profitability, has positioned it as a stable investment with potential for long-term appreciation.
Company Overview
BDX manufactures and sells a wide range of medical devices, instrument systems, and reagents. Its products are used in various healthcare settings, including hospitals, laboratories, and clinics. The company operates in over 190 countries and has a diverse customer base.
Fundamental Analysis
Revenue: BDX has consistently grown its revenue, with a 0.069% increase in the latest quarter.
Earnings: The company's diluted EPS has remained stable, with a 5.94% increase in the latest quarter.
Profitability: BDX maintains healthy profit margins, with a gross profit margin of 0.0713 and an operating margin of 0.152.
Valuation: The company's trailing PE ratio of 39.5 indicates that it is currently trading at a premium valuation compared to the industry average.
Dividend: BDX pays a quarterly dividend of $3.76 per share, resulting in a dividend yield of 0.0168%.
Technical Analysis
Trend: BDX is currently trading within a range between $217.86 and $246.89.
Moving Averages: The 50-day moving average is above the 200-day moving average, indicating a potential bullish trend.
Support and Resistance: The stock has found support at around $231.22 and resistance at around $240.
Short Term Outlook
In the short term, BDX may experience some volatility due to market fluctuations. However, the company's strong fundamentals and positive analyst sentiment suggest that it is likely to maintain its current price range or potentially move higher.
Long Term Outlook
BDX has a solid track record of growth and profitability, which is expected to continue in the long term. The company's investments in innovation and its strong global presence position it well to benefit from the growing demand for medical technology.
Analyst Recommendations
Analysts have a generally positive outlook on BDX, with 6 strong buy ratings, 8 buy ratings, and 4 hold ratings. The average analyst target price is $277.94, indicating a potential upside of approximately 20%.
